Challenges in the Management of Post-COVID-19 Pulmonary Fibrosis for the Latin American Population.
Iván Cherrez-OjedaAngela Dayana Williams-JacquezLaura Gochicoa-RangelGénesis Camacho-LeonHans MautongKarla Robles-VelascoMarco Faytong-HaroPublished in: Journal of personalized medicine (2022)
This commentary aims to highlight some of the major issues (with possible solutions) that the Latin American region is currently dealing with in managing post-COVID-19 pulmonary fibrosis. Overall, there is little evidence for successful long-term COVID-19 follow-up treatment. The lack of knowledge regarding proper treatment is exacerbated in Latin America by a general lack of resources devoted to healthcare, and a lack of availability and access to multidisciplinary teams. The discussion suggests that better infrastructure (primarily multicenter cohorts of COVID-19 survivors) and well-designed studies are required to develop scientific knowledge to improve treatment for the increasing prevalence of pulmonary fibrosis in Latin America.